No Data
hubei biocause pharmaceutical (000627.SZ) appointed Long Fei as General Manager and CFO.
Hubei Biocause Pharmaceutical (000627.SZ) announced that the board of directors will hold the tenth session on December 6, 2024...
A-shares midday review: The Shanghai index climbed back above 3400 points, the chinext price index rose by 2.49%, and the AIGC concept saw a full breakout.
As of noon, the Shanghai Composite Index rose 1.23% to 3410.36 points, the Shenzhen Component Index rose 1.79%, and the chinext price index rose 2.49%.
Hubei Biocause Pharmaceutical (000627.SZ): has not yet repurchased the company's shares.
Gelonghui December 2nd| Hubei Biocause Pharmaceuticals (000627.SZ) announced that as of the close of November 29, 2024, the company's stock price was 4.19 yuan per share, exceeding the upper limit of the company's stock repurchase price. The company has repurchased a total of 0 shares of the company's stock through a designated securities account for stock repurchase using centralized bidding trading, accounting for 0.00% of the company's current total share capital.
Strong Week for Hubei Biocause Pharmaceutical (SZSE:000627) Shareholders Doesn't Alleviate Pain of Five-year Loss
Biocause Pharma's Insurance Unit Logs 31 Billion Yuan Insurance Premium Income in January-October Period
Tianmao Group: Report for the third quarter of 2024
